QUOTE AND NEWS
FierceBiotech  Apr 24  Comment 
AstraZeneca's partnership spree of the last two months has gone Down Under. As the company shrinks its internal research work force, AstraZeneca ($AZN) has tapped Brisbane, Australia-based Alchemia to hunt for small molecule drugs against multiple...
Sydney Morning Herald  Apr 23  Comment 
Alchemia has struck a deal with AstraZeneca to search for disease-treating small molecules, which could be worth around $240 million.     
The Australian  Dec 23  Comment 
ALCHEMIA has blamed "technical issues" for the failure of a US capital raising and related spin-off of its Audeo Oncology unit.
The Australian  Nov 11  Comment 
SHARES in Australian biotech Alchemia are expected to soar in the US.
FierceBiotech  Jul 9  Comment 
Australia's Alchemia is splitting off its cancer drug work into a new company, which has filed for an IPO designed to raise up to $60 million. Audeo Oncology shares will be listed on the Australian exchange as well as on Nasdaq, according to...
Globe Newswire  May 17  Comment 
NEW YORK, May 17, 2012 (GLOBE NEWSWIRE) -- Panache Beverage, Inc. (OTCQB:WDKA), an alcoholic beverage company specializing in the development, global sales and marketing of spirits brands, today announced that Alchemia Infused Vodka has launched its
Globe Newswire  May 9  Comment 
NEW YORK, May 9, 2012 (GLOBE NEWSWIRE) -- Panache Beverage, Inc. (OTCQB:WDKA), an alcoholic beverage company specializing in the development, global sales and marketing of spirits brands, today announced that its current portfolio of brands including
Sydney Morning Herald  Mar 11  Comment 
Investing in biotechs could easily be called 'molecular roulette'.
Marketwire  Feb 28  Comment 
BRISBANE, AUSTRALIA -- (Marketwire) -- 02/28/12 -- Alchemia Limited, Inc (ASX: ACL), today announced that Peter Smith, Alchemia's Chief Executive Officer, is scheduled to present at the 32nd Annual Cowen Health Care Conference in Boston on Monday,
Sydney Morning Herald  Feb 6  Comment 
Alchemia says it is happy with the market share achieved by its blood-thinning drug, fondaparinux, in the US.





 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki